| [1] | Yikai WANG, Fengping WU, Chenrui LIU, Miao HAO, Shasha LYU, Miaomiao ZHANG, Shuangsuo DANG, Xin ZHANG. Dynamic change and significance of Mindin protein in chronic hepatitis B treated with PEG-IFNα-2b[J]. Journal of Clinical Hepatology, 2024, 40(1): 52-57. doi: 10.12449/JCH240110 |
| [2] | Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009 |
| [3] | Jinjin LIU, Mengyang ZHANG, Yameng SUN, Hong YOU. Evolution in the indications for anti-viral therapy in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2023.06.007 |
| [4] | Yanna LIU, Mingwei LI, Leijie WANG, Hong ZHAO, Shuangsuo DANG, Xiangmei CHEN, Jingmin ZHAO, Fengmin LU. HBeAg-negative chronic HBV-infected individuals with normal alanine aminotransferase and an age of ≤30 years should be taken seriously when expanding anti-HBV treatment for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(7): 1477-1481. doi: 10.3969/j.issn.1001-5256.2022.07.006 |
| [5] | Gao XiaoHong, Cheng Ni, Cao JiaoJiao. Clinical cure in patients with hepatitis B cirrhosis treated with pegylated interferon α-2b: A case report[J]. Journal of Clinical Hepatology, 2020, 36(6): 1347-1348. doi: 10.3969/j.issn.1001-5256.2020.06.031 |
| [6] | Chen Xi, Zhao WenJing, Sun Yan, Yin HaiYan. Value of baseline HBsAg quantification in predicting the clinical effect of pegylated interferon α-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(8): 1723-1726. doi: 10.3969/j.issn.1001-5256.2020.08.009 |
| [7] | Ji WeiJia, Yan XueBing. Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B [J]. Journal of Clinical Hepatology, 2019, 35(2): 309-314. doi: 10.3969/j.issn.1001-5256.2019.02.013 |
| [8] | Wu XiaoNing, Zhang Wei, Zhou JiaLing, Wang Lin, Sun YaMeng, Meng TongTong, Wang XiaoMing, You Hong, Ou XiaoJuan, Jia JiDong. Influence of baseline HBV DNA level on the clinical outcome of patients with compensated hepatitis B cirrhosis after antiviral therapy[J]. Journal of Clinical Hepatology, 2018, 34(8): 1678-1682. doi: 10.3969/j.issn.1001-5256.2018.08.017 |
| [9] | Guo ChunXia, Li Jia, Xu CengLi, Guo Jie, Zhai Lu, Han Xu. Impact of HBV DNA detection methods on evaluating the clinical effect of PEG-IFNɑ-2b in treatment of HBeAg-positive chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2017, 33(4): 664-667. doi: 10.3969/j.issn.1001-5256.2017.04.013 |
| [10] | Liu YuanYuan, Guo XiaoLin, Jin JingLan. One case of nephrotic syndrome complicated by decompensated hepatitis C cirrhosis treated with hormone and interferon[J]. Journal of Clinical Hepatology, 2014, 30(1): 72-73. doi: 10.3969/j.issn.1001-5256.2014.01.020 |
| [11] | Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014 |
| [12] | Yan ShuangHuan, Cao ZhiChen. Changes in Toll-like receptor 4 expression on the surface of peripheral blood monocytes in patients with chronic hepatitis B during interferon treatment [J]. Journal of Clinical Hepatology, 2012, 28(11): 828-830. |
| [13] | Shi QingFeng, Song JiKui, Zhang YingXin, Yuan JianGuo, Wang SiKui, Li QingFang, Zhao HongKui. Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b[J]. Journal of Clinical Hepatology, 2011, 27(12): 1285-1287+1300. |
| [14] | Wang Xu, Yuan ChengMin, Wu AnZhao, Lu Yong, Zhao YuJuan. The observation of anti-viral effect of matrine combined with interferon α-2b on the chronic hepatitis B patients with mild transaminase elevations[J]. Journal of Clinical Hepatology, 2011, 27(5): 488-489+502. |
| [15] | Jin Rui, Zhang ShiBin, Bian XinQu, Lu ChengZhen, Liu ZhongSheng, Guo XinHui. Clinical study of IFNα-2b alone or in combination with lamivudine for HBeAg positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(6): 617-619. |
| [17] | Li Jun, Chen XinYue, Zhao Hong, Yu YanYan, Si ChongWen, Han ZhongHou, Zhang WenJin, Chen YuPing, Chen Yong, Wang GuiQiang, Yu Min, Gong WeiBo, Xu JingHang, Wang Jun, Lin XiaoHong, Li XueYing. The relationship of hepatitis B virus genotypes and efficacy of lamivudine and interferon alpha 2b in the treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(3): 169-171. |
| [18] | Luo WeiMin, Zhang YingChun, Liu ZhongJing. Clinical Observation about Entecavir in Treating Chronic Hepatitis B at the Initial Stage.[J]. Journal of Clinical Hepatology, 2008, 24(1): 26-28. |
| [19] | Xiao Yang, Hu CaoHan, Zhou YueJin, Xie QingRong, Zhu BingXing, Hu Xia, Wang KaiJian, Zhang WenJing. Effect of hepatitis B virus genotypes on response to interferon α2b in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2006, 22(2): 105-106. |
DownLoad: